ERNA · Ernexa Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Charles Cherington | ▲ Buy | Open Market | 6,779,440 Shares held | 2/10/2026 | View profile |
| John D. Halpern 10% Owner | ▲ Buy | Open Market | 450,961 Shares held | 12/2/2022 | View profile |
| Nicholas Jason Singer | ▲ Buy | Open Market | 266,214 Shares held | 12/2/2022 | View profile |
| Roger Sidhu Chief Medical Officer | ▲ Buy | Option Exercise | 20,163 Shares held | 9/20/2022 | View profile |
| Kevin DAmour Chief Scientific Officer | ▼ Sell | Tax Withholding | 11,496 Shares held | 6/28/2022 | View profile |
| Sandra M. Gurrola Vice President of Finance | ▲ Buy | Option Exercise | 110 Shares held | 6/21/2025 | View profile |
Transaction History
| Charles Cherington | ▲ Buy | Open Market | 4,000,000 | $2.0M | 2/10/2026 |
| Sandra M. Gurrola | ▲ Buy | Option Exercise | 30 | — | 6/21/2025 |
| Charles Cherington | ▲ Buy | Open Market | 21,241,163 | $2.2M | 6/9/2025 |
| Charles Cherington | ▲ Buy | Open Market | 3,768,397 | $394K | 4/2/2025 |
| Charles Cherington | ▲ Buy | Open Market | 261,756 | — | 10/29/2024 |
| Charles Cherington | ▲ Buy | Open Market | 4,768,783 | — | 10/29/2024 |
| Charles Cherington | ▲ Buy | Open Market | 1,237,762 | — | 10/29/2024 |
| Charles Cherington | ▲ Buy | Open Market | 5,420,823 | — | 10/29/2024 |
| Charles Cherington | ▲ Buy | Open Market | 1,562,988 | — | 10/29/2024 |
| Charles Cherington | ▼ Sell | Other | 2,819,546 | $1.4M | 10/29/2024 |
| Sandra M. Gurrola | ▲ Buy | Option Exercise | 437 | — | 6/21/2024 |
| Sandra M. Gurrola | ▼ Sell | Tax Withholding | 180 | $349 | 6/21/2024 |
| Sandra M. Gurrola | ▲ Buy | Option Exercise | 438 | — | 6/21/2023 |
| Sandra M. Gurrola | ▼ Sell | Tax Withholding | 179 | $444 | 6/21/2023 |
| Nicholas Jason Singer | ▲ Buy | Open Market | 70,822 | $232K | 12/2/2022 |
| Nicholas Jason Singer | ▲ Buy | Open Market | 212,464 | $697K | 12/2/2022 |
| John D. Halpern | ▲ Buy | Open Market | 335,920 | $1.1M | 12/2/2022 |
| Charles Cherington | ▲ Buy | Open Market | 261,756 | $859K | 12/2/2022 |
| Roger Sidhu | ▲ Buy | Option Exercise | 20,163 | — | 9/20/2022 |
| Kevin DAmour | ▲ Buy | Option Exercise | 17,573 | — | 6/28/2022 |
| Kevin DAmour | ▼ Sell | Tax Withholding | 6,077 | $3K | 6/28/2022 |
| Sandra M. Gurrola | ▲ Buy | Option Exercise | 8,750 | — | 6/21/2022 |
| Sandra M. Gurrola | ▼ Sell | Tax Withholding | 3,586 | $2K | 6/21/2022 |
| Charles Cherington | ▼ Sell | Other | 92 | $0 | 6/1/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Ernexa Therapeutics reports safety data and new oncology leadership
Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.
Ernexa Therapeutics reports safety data and new oncology leadership. Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.